|
|
||||||||
|
FIGURE 3. 18F-FDG uptake in bone marrow (A) and spleen (B) in patients (n = 16) at baseline and after single doses of adjuvant pegfilgrastim (scan 2). Average SULmean in bone marrow and spleen is significantly higher on scan 2 (P < 0.0001).
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |